532384.BO Stock Analysis
53
Neutral
Based on Eyestock quantitative analysis, 532384.BO`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Market cap $B
0.01
Dividend yield
2.04 %
Shares outstanding
10.25 B
Tyche Industries Ltd. engages in the manufacture and processing of active pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana and currently employs 166 full-time employees. The company went IPO on 2000-09-25. The firm operates through the Bulk Drugs segment. Its APIs include Sertraline HCI, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Atazanavir, Rupatadine Fumarate, Glucosamine HCI, Glucosamine Sulfate KCL, Glucosamine Sulfate NaCl, Nitrofurantoin Monohydrate, Nitrofurantoin Anhydrous and Nitrofurantoin Macrocrystal and others. Its intermediates include 4-(3,4-Dichlorophenyl)-1-tetralone, 1-Benzylpiperidine-4-Carboxaldehyde (BPCA), 3-Hydroxymethyl quinuclidine Hcl, and others. Its chiral intermediates include S-(+)-3-Quinuclidinol, R-(-)-3-Quinuclidinol and others. The firm's nutraceuticals include Glucosamine Hydrochloride, Glucosamine Sulphate Potassium Chloride and Glucosamine Sulphate Sodium Chloride.